Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ONC206 |
Synonyms | |
Therapy Description |
ONC206 is an imipridone derivative that activates the stress response pathway, inhibits the p38MAPK/ERK and c-Myc pathways, glycolysis and oxidative phosphorylation, potentially leading to inhibition of cell proliferation, migration and tumor growth (PMID: 28489985, PMID: 32867127, PMID: 30037819) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ONC206 | ONC 206|ONC-206 | ONC206 is an imipridone derivative that activates the stress response pathway, inhibits the p38MAPK/ERK and c-Myc pathways, glycolysis and oxidative phosphorylation, potentially leading to inhibition of cell proliferation, migration and tumor growth (PMID: 28489985, PMID: 32867127, PMID: 30037819) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04732065 | Phase I | ONC206 | ONC206 for Treatment of Newly Diagnosed or Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant Brain Tumors (PNOC 023) | Recruiting | USA | CHE | 0 |
NCT04541082 | Phase I | ONC206 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | Recruiting | USA | 0 |